Overview

A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator polyICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Ludwig Institute for Cancer Research

Collaborators:

Cancer Research Institute, New York City
MedImmune LLC

Treatments:

Antibodies
Antibodies, Monoclonal
Carboxymethylcellulose Sodium
Durvalumab
Poly I-C
Poly ICLC
Tremelimumab